Considering the enhancement effect of sorafenib on graft-versus-leukemia (GVL), we conducted a retrospective exploratory study to compare conventional therapeutic strategies combined with or without sorafenib for AML patients with FLT3 wild-type who relapsed after allo-HSCT. Here, FLT3 is linked to leukemia.